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Purpose: Anal cancer is a rare disease in Korea, and thus survival analyses are limited by small sample sizes. This study 
used the Korea Central Cancer Registry (KCCR) for a survival analysis and for assessing characteristics of anal cancer in a 
large sample of Koreans.
Methods: From the KCCR, data on 3,615 patients who were diagnosed and treated for anal cancer from 1993 to 2015 were 
retrieved. Clinicopathologic variables including age, sex, histological type, and Surveillance Epidemiology and End Re-
sults (SEER) stage were reviewed, and a survival analysis was performed according to these variables.
Results: The 5-year relative survival rate improved from 39.7% in 1993–1995 to 66.5% in 2011–2015. Squamous cell carci-
noma was the most common and showed the highest survival rate. Males and older patients (≥40 years and ≥70 years) 
showed poor prognoses.
Conclusion: The survival rate for anal cancer in Korea has improved steadily over time. The characteristics related to sur-
vival were the histological type, sex, and age. These statistics will be fundamental for future Korean anal cancer research.
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INTRODUCTION
Cancer of the anal canal or the perianal region is a rare malignant 
disease. It has been estimated that approximately 14,500 cases of 
anal cancer in women and 12,500 in men occurred in 2008 
worldwide, but the incidence is increasing in high-income coun-
tries [1]. Anal cancer is composed of various histological types, 
including squamous cell carcinoma, adenocarcinoma, and mela-
noma. Anal cancer in Korea is very rare accounting for 0.1% of 
the cancer incidence [2]. It occurs mostly in the elderly, especially 
those aged over 60 years.
Squamous cell carcinoma is known to be the most frequent type 
of anal cancer due to it being caused by the relatively common 
human papillomavirus (HPV). It is also found in immunosup-
pressed individuals (e.g., those infected by human immunodefi-
ciency virus [HIV]) [3, 4]. Lifestyle factors such as smoking or a 
high number of sexual partners can increase the risk [5]. High-
grade anal intraepithelial neoplasia has been shown to progress to 
invasive anal cancer in HIV-positive or immunocompromised 
patients [6]. In Korea, the high-risk population with the above 
factors is increasing and the incidence of anal squamous cell car-
cinoma has been increasing over time [7].
The rare incidence and mixed nature of various histological 
types have limited anal cancer research, and the sample sizes of 
such studies are always small. The Korea Central Cancer Registry 
(KCCR) started as a nationwide, hospital-based cancer registry 
driven by the Ministry of Health and Welfare in 1980. Since 1999, 
the KCCR has grown to cover the whole population under the 
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population-based cancer registry program. The KCCR thus pro-
vides sufficient quantity of data for the basic understanding of 
clinical features of Korean anal cancer. The purpose of the current 
study was to review the KCCR anal cancer data and to analyze 
survival according to various clinical features.
METHODS
From the KCCR, we extracted data on 3,615 patients with anal 
cancer who were diagnosed between 1993 and 2015. The primary 
cancer was first classified based on the International Classification 
of Disease for Oncology, 3rd edition [8], and then converted to 
the classification based on the International Classification of Dis-
eases, 10th edition [9]. Histological types were categorized as (1) 
squamous cell carcinoma, (2) adenocarcinoma, (3) melanoma, (4) 
neuroendocrine tumor, (5) epithelial neoplasm, (6) sarcoma, and 
(7) others. Patient age, sex, and clinical data (such as tumor type 
and stage) were analyzed. This study was exempted from approval 
and informed consent by the Institutional Review Board of the 
Severance Hospital of the Yonsei University Health System.
The study time periods were split into 1993–1995, 1996–2000, 
2001–2005, 2006–2010, and 2011–2015. For the period of 2011–
2015, the Surveillance Epidemiology and End Results (SEER) 
stage system (local, regional, distant, and unknown) was used. 
The SEER local stage included tumors confined to the original 
organ (anus without invasion of adjacent organs, such as the va-
gina, urethra, bladder, and lymph-node metastasis). Regional dis-
ease included tumors with adjacent organ invasion or regional 
lymph-node metastasis. Distant disease included those with dis-
tant site metastasis. A comparison of SEER stages across TNM 
stages is shown in Supplementary Table 1. Patients were also 
grouped by age, with young patients defined as those in which the 
cancer developed prior to the age of 40 years, and advanced pa-
tients defined as those in which cancer developed after the age of 
70 years. The survival rates of the above 2 age groups were respec-
tively compared with that of the other age group (i.e., those be-
tween ages 40 and 70 years).
The 5-year relative survival rate (RSR), adjusted for the expected 
mortality of the general population of the same age and sex, was 
calculated using the Ederer II method [10]. The algorithm in SAS 
9.3 (SAS Institute Inc., Cary, NC, USA) described by Dickman et 
al. [11] was applied for relative survival analysis, with minor mod-
ifications. Asymmetric observed survival confidence intervals 
(CIs) were made from log-transformed standard errors estimated 
using the Greenwood method. The RSR confidence limits were 
derived by dividing the observed survival limits by the corre-
sponding expected survival rate.
RESULTS
Histological Types and Stages of Anal Cancer
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cases in 1993–1995 to 1,062 cases in 2011–2015. Squamous cell 
carcinoma was the most common histological type, comprising 
more than half of all cases from 1996 to 2015. Adenocarcinoma 
increased from 25.4% in 1993–1995 to 34.8% in 2011–2015. Mel-
anoma, neuroendocrine tumors, epithelial neoplasm, and sar-
coma form a small portion and show similar incidences during 
whole time period (Table 1; Figs. 1 and 2). The proportion of anal 
cancer in 2011–2015 with a regional stage designation across both 
sexes was 44.0%; 33.5% were local stage tumors, and 9.7% were 
distant stage tumors. This order was evident among both male 
and female patients when analyzed independently (Table 2).
Relative Survival Rates for Anal Cancer by Histological 
Type, Stage, and Patient’s Sex and Age
The 5-year RSRs by time period according to histological type are 
summarized in Table 1. The 5-year RSR increased from 39.7% 
(95% CI, 34.1%–45.4%) during 1993–1995 to 66.5% (95% CI, 
62.3%–70.5%) during 2011–2015. Although improvements over 
Fig. 1. Trends in the proportion of anal cancer by time period from 1993 to 2015 according to histologic type.
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time occurred regardless of histological type, RSRs for melanoma 
were consistently the lowest (in all periods). The local stage 
showed a good 5-year RSR of 76.2% in 2011–2015. The regional 
stage showed a lower 5-year RSR of 64.9%. The distant stage 
showed a poor 5-year RSR of 35%. Female was related to better 
RSR in all SEER stages from 2011 to 2015 (Table 2). The 5-year 
RSRs were also compared among different age groups. The 
young-aged cancer group (less than 40 years) showed better sur-
vival compared to those over 40 years (Table 3). The patients aged 
70 years or older with a distant stage had a worse RSR (Table 4).
DISCUSSION
This study demonstrated that anal cancer has increased during 
the past 20 years in Korea. The observed increased incidence oc-
curred in all histologic types of anal cancer. In particular, the most 
common squamous cell carcinoma incidence has increased sig-
nificantly. In the same time period, the 5-year RSR increased sig-
nificantly in all histologic types according to the time period from 
1993 to 2015. Survival was better for women, patients <40 years 
and <70 years.
The worldwide incidence of anal cancer has been increasing—
either in both sexes or in women—in many populations, espe-
cially in the United States, Europe, and Australia [1]. In these 
populations, anal squamous cell carcinoma was substantially 
more common than other histological subtypes and was the main 
contributor to the increase in the anal cancer incidence. The inci-
dence of anal squamous cell carcinoma is lower in Asia and Asian 
populations have seen little change. However, our study observed 
an increasing incidence of anal squamous cell carcinoma over 
time. The reason for the increasing anal squamous cell carcinoma 
incidence rates in many populations is unclear, but is likely to re-
flect changes in the prevalence of environmental risk factors. In-
fection with HPV is an established risk factor for anal cancer [3]. 
Factors that lead to persistent anal HPV infection may thus be of 
great importance in the risk of developing anal cancer. These fac-
tors include concurrent cervical HPV infection and other HPV-
related anogenital diseases, receptive anal intercourse and proba-
bly tobacco smoking [12, 13]. Furthermore, concomitant infec-
tion with HIV indirectly increases the risk of anal cancer by im-
munosuppression and increased replication of HPV [6, 14]. A 
number of studies have reported an association between tobacco 
smoking and anal cancer [5, 15]. Immunosuppression following 
transplantation, and with some diseases, are associated with an 
increased risk of anal cancer [16]. In a previous report about char-
acteristics and survival of anal cancer in Koreans [7], we observed 
the increasing incidence of anal squamous cell carcinoma, but the 
risk factors and the reason for the increasing incidence were not 
investigated in this study. An investigation of risk factors for the 
increasing incidence of anal squamous carcinoma in Korea is 
needed.
The treatment strategy for anal cancer mainly depends on the 
histological type. For squamous cell carcinoma, the most com-
mon type of anal cancer, chemoradiation therapy has been the 
standard treatment and has provided considerable outcomes [17]. 
The 5-year net survival increased during these 30 years from 
63.4% to 72.7%. Improved survival has also been observed in 
other countries [18]. These population-based results of real-world 
Table 2. Five-year relative survival rate (RSR) of patients with anal cancer by sex according to SEER stage in 2011–2015
SEER stage
Both sexes Male Female
No. (%) 5-Year RSR (95% CI) No. (%) 5-Year RSR (95% CI) No. (%) 5-Year RSR (95% CI)
Overall 1,062 66.5 (62.3–70.5) 459 66.1 (59.6–72.1) 603 66.9 (61.2–72.1)
Local 467 (44.0) 76.2 (69.7–81.8) 207 (45.1) 72.5 (61.9–81.5) 260 (43.1) 79.1 (70.7–85.8)
Regional 356 (33.5) 64.9 (56.8–72.1) 133 (29.0) 64.3 (51.3–75.7) 223 (37.0) 65.6 (55.2–74.5)
Distant 103 (9.7) 35 (24–46.5) 47 (10.2) 33.2 (17.6–50.3) 56 (9.3) 36.6 (21.8–52.0)
Unknown 136 (12.8) 61.3 (50.4–70.9) 72 (15.7) 70.3 (56.1–81.6) 64 (10.6) 50.1 (33.1–65.6)
SEER, Surveillance Epidemiology and End Results; CI, confidence interval.
Table 3. Five-year relative survival rate (RSR) for patients with anal 
cancer aged <40 years and ≥40 years according to SEER stage in 2011–
2015
SEER stage







Overall 38 79.5 (60.9–90.0) 1,024 65.9 (61.5–70.1)
Distant disease 5 40.3 (5.2–75.8) 98 34.4 (22.9–46.5)
SEER, Surveillance Epidemiology and End Results; CI, confidence interval.
Table 4. Five-year relative survival rate (RSR) for patients with anal 
cancer aged <70 years and ≥70 years according to SEER stage in 2011–
2015
SEER stage







Overall 668 76 (71.3–80.1) 394 48.7 (40.4–56.9)
Distant disease 57 37.8 (23.0–52.6) 46 32.4 (16.6–50.6)
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data, and the 5-year survival of patients who received curative 
chemoradiation therapy of 76.4%, seem to be comparable with 
survival results obtained in clinical trials, and demonstrate the 
previously known dependency on disease stage [19]. During these 
30 years, improvements in imaging have resulted in better staging, 
RT techniques have evolved with more precise radiation dose de-
livery and less risk of side effects [20], and clinical trials have in-
vestigated the optimal chemotherapy regimens in combination 
with RT [19, 21]. Our study indicated that the survival rate for 
anal squamous cell carcinoma in Korea has also been improving 
since the early 1990s. However, there is no detailed information 
about the change in treatment modalities such as chemothera-
peutic agents, radiotherapy techniques, and surgical procedures. 
More investigation and analyses are needed to know the exact 
reason for the increasing incidence and survival of anal squamous 
cell carcinoma.
Anal adenocarcinoma, the second-most common type, is con-
sidered similar to rectal cancer. The incidence of this type was re-
ported to be stable in contrast to that of squamous cell carcinoma, 
which showed an increasing trend [22]. In contrast, our study 
shows the increasing incidence of anal adenocarcinoma accord-
ing to the time period from 1993 to 2015. The recommended 
treatment strategy for this type of anal cancer is to follow that of 
low rectal cancer, which includes chemoradiation therapy fol-
lowed by radical surgery. Not infrequently, this type is related to 
Crohn disease with long-lasting anal fistula [23].
The third-most common type, anal melanoma, is a rare disease 
in Korea. Although improving, the prognosis for melanoma re-
mains poor. Anal melanoma is usually diagnosed at later stages 
and known to be refractory to chemoradiation therapy [24, 25]. 
Radical surgery remains effective in select cases and can achieve 
long-term survival [26, 27].
There were slightly more female patients with anal cancer in Ko-
rea and their prognoses were found to be better than those of 
male patients. In Korea, most female patients with solid organ 
cancers usually have a better prognosis [28]. Previous reports 
demonstrated that male patients with anal cancer might have 
worse outcomes after chemoradiation therapy especially for squa-
mous cell carcinoma [29].
In this study, the advanced-aged patients (70 years or older) 
were found to have worse survival than the others. This observa-
tion may be attributed to less vigorous treatment in the advanced-
aged group. Recent studies, however, suggested that standard 
treatment could be well-tolerated and result in satisfactory onco-
logical outcomes in elderly patients [30]. In Korea, where the pro-
portion of the elderly population is growing, the treatment strat-
egy for elderly patients with anal cancer needs to be assessed more 
carefully.
To summarize, the present study provides essential information 
regarding the clinical characteristics and survival of Korean pa-
tients with anal cancer.
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